Want to see ERAS full AI Analyst Report?
ERAS Stock Chart & Stats
$19.49
-$0.24(-1.26%)
At close: 4:00 PM EDT
$19.49
-$0.24(-1.26%)
Day’s Range― - ―
52-Week Range$2.11 - $24.28
Previous Close$19.1
Volume3.53M
Average Volume (3M)5.34M
Market Cap
$5.11B
Enterprise Value$5.48B
Total Cash (Recent Filing)$268.74M
Total Debt (Recent Filing)$44.71M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding349,762,020
10 Day Avg. Volume5,963,307
30 Day Avg. Volume5,338,670
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.74K
Enterprise Value/Ebitda-19.28
Forecast
1Y Price Target
$24.14Price Target Upside23.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLow leverage provides Erasca with greater financial flexibility than highly indebted peers while it funds clinical development. The relatively modest debt burden may reduce near-term solvency pressure and leave more room to allocate capital toward advancing its oncology pipeline.
Regulatory MomentumFast Track Designation gives ERAS-0015 potential access to more frequent FDA interactions and expedited development or review pathways. Although approval is not assured, the designation can improve regulatory engagement and support the program’s competitive position in an area of high unmet need.
R&D LeadershipAppointing an experienced oncology leader strengthens scientific and clinical oversight as Erasca advances multiple RAS-focused programs. Relevant expertise across major biopharma and academic institutions could support trial execution, development decisions, and progress toward potential commercialization.
Bears Say
No Commercial RevenueErasca has no established commercial revenue base to offset research, clinical, and administrative expenses. Its future operating revenue depends on successful development, regulatory approval, and commercialization or partnering, making business performance highly dependent on pipeline outcomes.
Persistent Cash BurnPersistent negative operating and free cash flow means the business is not yet self-funding and must continue using available cash or external capital to support development. This limits financial resilience and keeps funding requirements tied to the pace and cost of clinical programs.
Equity DilutionThe sizable equity offering improves liquidity for research and development, but issuing additional shares dilutes existing ownership. Repeated reliance on equity financing could raise the capital required to advance the pipeline while reducing each existing shareholder’s proportional participation.
Erasca News
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $2.10 and its highest was $24.28 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $5.11B.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Nov 11, 2026 which is in 19 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.029.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.13.
How many shares outstanding does Erasca have?
Erasca has 349,762,020 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went up 0.766%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Erasca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.14 (23.87% Upside)
$24.14 (23.87% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 75%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 74.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
508.82%
12-Months-Change
Fundamentals
Return on Equity
-80.43%
Trailing 12-Months
Asset Growth
-2.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Erasca
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$24.14
▲(23.87% Upside)
Technical Analysis
Kura Oncology
―
IDEAYA Biosciences
―
Relay Therapeutics
―
Nuvation Bio
―
Tyra Bioscience
―
Ownership Overview
9.65% Insiders
11.34% Mutual Funds
1.27% Other Institutional Investors
63.76% Public Companies and
Individual Investors